|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for EIF4E2 |
 Gene summary |
| Basic gene Info. | Gene symbol | EIF4E2 |
| Gene name | eukaryotic translation initiation factor 4E family member 2 | |
| Synonyms | 4E-LP|4EHP|EIF4EL3|IF4e | |
| Cytomap | UCSC genome browser: 2q37.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001276336.1, NM_001276337.1,NM_001282958.1,NM_004846.3, | |
| Description | eIF-4E type 2eIF4E-like cap-binding proteineIF4E-like protein 4E-LPeukaryotic translation initiation factor 4E homologous proteineukaryotic translation initiation factor 4E type 2eukaryotic translation initiation factor 4E-like 3mRNA cap-binding pro | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 605895 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000135930 | ||
| HPRD : 05798 | ||
| Vega : OTTHUMG00000133256 | ||
| Protein | UniProt: O60573 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_EIF4E2 | |
| BioGPS: 9470 | ||
| Pathway | NCI Pathway Interaction Database: EIF4E2 | |
| KEGG: EIF4E2 | ||
| REACTOME: EIF4E2 | ||
| Pathway Commons: EIF4E2 | ||
| Context | iHOP: EIF4E2 | |
| ligand binding site mutation search in PubMed: EIF4E2 | ||
| UCL Cancer Institute: EIF4E2 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for EIF4E2 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | R67 | R66M | LUAD | 1 | Y58 | Y60S | LUAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for EIF4E2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | Y58 | Y60S | -1.3952308 | R67 | R66M | -0.36816622 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for EIF4E2 from PDB |
| Top |
| Differential gene expression and gene-gene network for EIF4E2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for EIF4E2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for EIF4E2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of EIF4E2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | MGT | 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE | 2jgb | A | R67 | III | Peptide ligand (ARG,ILE,ILE,TYR,ASP,ARG,LYS,PHE,LEU,MET,GLU,CYS,ARG,ASN,SER,PRO) | 2jgb | A | Y58 | III | Peptide ligand (ARG,ILE,ILE,TYR,ASP,ARG,LYS,PHE,LEU,MET,GLU,CYS,ARG,ASN,SER,PRO) | 2jgc | A | Y58 |
| Top |
| Conservation information for LBS of EIF4E2 |
| Multiple alignments for O60573 in multiple species |
| LBS | AA sequence | # species | Species | E125 | IKPMWEDDANK | 2 | Homo sapiens, Mus musculus | E125 | VKPVWEDPANC | 1 | Caenorhabditis elegans | E149 | ASRCWENLILA | 2 | Homo sapiens, Mus musculus | E149 | STRIWENLLMA | 1 | Caenorhabditis elegans | E158 | LAMLGEQFMVG | 2 | Homo sapiens, Mus musculus | E158 | MAIIGEQFLVG | 1 | Caenorhabditis elegans | E164 | QFMVGEEICGA | 2 | Homo sapiens, Mus musculus | E164 | QFLVGDELCGA | 1 | Caenorhabditis elegans | E92 | TFASVEQFWRF | 1 | Homo sapiens | E92 | TFASVEQFWKF | 1 | Mus musculus | E92 | IMKSVEQFWSI | 1 | Caenorhabditis elegans | F5 | 3 | Homo sapiens, Mus musculus, Caenorhabditis elegans | G157 | ILAMLGEQFMV | 2 | Homo sapiens, Mus musculus | G157 | LMAIIGEQFLV | 1 | Caenorhabditis elegans | G163 | EQFMVGEEICG | 2 | Homo sapiens, Mus musculus | G163 | EQFLVGDELCG | 1 | Caenorhabditis elegans | H110 | GDLTGHSDFHL | 2 | Homo sapiens, Mus musculus | H110 | TEMCDKADIHF | 1 | Caenorhabditis elegans | H54 | PGPAEHPLQYN | 2 | Homo sapiens, Mus musculus | H54 | -GSDDHQLQYS | 1 | Caenorhabditis elegans | L153 | WENLILAMLGE | 2 | Homo sapiens, Mus musculus | L153 | WENLLMAIIGE | 1 | Caenorhabditis elegans | M123 | EGIKPMWEDDA | 2 | Homo sapiens, Mus musculus | M123 | TGVKPVWEDPA | 1 | Caenorhabditis elegans | M161 | LGEQFMVGEEI | 2 | Homo sapiens, Mus musculus | M161 | IGEQFLVGDEL | 1 | Caenorhabditis elegans | N150 | SRCWENLILAM | 2 | Homo sapiens, Mus musculus | N150 | TRIWENLLMAI | 1 | Caenorhabditis elegans | P55 | GPAEHPLQYNY | 2 | Homo sapiens, Mus musculus | P55 | GSDDHQLQYSY | 1 | Caenorhabditis elegans | Q159 | AMLGEQFMVGE | 2 | Homo sapiens, Mus musculus | Q159 | AIIGEQFLVGD | 1 | Caenorhabditis elegans | Q57 | AEHPLQYNYTF | 2 | Homo sapiens, Mus musculus | Q57 | DDHQLQYSYTF | 1 | Caenorhabditis elegans | R174 | AVVSVRFQEDI | 2 | Homo sapiens, Mus musculus | R174 | AVCSIRNQEDI | 1 | Caenorhabditis elegans | R67 | FWYSRRTPGRP | 2 | Homo sapiens, Mus musculus | R67 | FSYFMRPTGK- | 1 | Caenorhabditis elegans | T73 | TPGRPTSSQSY | 2 | Homo sapiens, Mus musculus | T73 | PTGK-FDPEDY | 1 | Caenorhabditis elegans | V91 | GTFASVEQFWR | 1 | Homo sapiens | V91 | GTFASVEQFWK | 1 | Mus musculus | V91 | GIMKSVEQFWS | 1 | Caenorhabditis elegans | W124 | GIKPMWEDDAN | 2 | Homo sapiens, Mus musculus | W124 | GVKPVWEDPAN | 1 | Caenorhabditis elegans | W95 | SVEQFWRFYSH | 1 | Homo sapiens | W95 | SVEQFWKFYSH | 1 | Mus musculus | W95 | SVEQFWSIMVH | 1 | Caenorhabditis elegans | Y58 | EHPLQYNYTFW | 2 | Homo sapiens, Mus musculus | Y58 | DHQLQYSYTFS | 1 | Caenorhabditis elegans | Y78 | TSSQSYEQNIK | 2 | Homo sapiens, Mus musculus | Y78 | FDPEDYASYVQ | 1 | Caenorhabditis elegans |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |